Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Oct 25, 2022

SELL
$273.83 - $305.53 $5.94 Million - $6.63 Million
-21,700 Reduced 93.53%
1,500 $0
Q2 2022

Aug 04, 2022

SELL
$234.96 - $292.55 $399,432 - $497,335
-1,700 Reduced 6.83%
23,200 $60,000
Q1 2022

Apr 14, 2022

BUY
$221.42 - $260.97 $4.87 Million - $5.74 Million
22,000 Added 758.62%
24,900 $143,000
Q4 2021

Jan 18, 2022

BUY
$177.01 - $223.45 $477,927 - $603,315
2,700 Added 1350.0%
2,900 $14,000
Q2 2021

Jul 19, 2021

SELL
$187.49 - $221.1 $281,235 - $331,650
-1,500 Reduced 88.24%
200 $1,000
Q1 2021

Apr 26, 2021

BUY
$207.02 - $241.31 $310,530 - $361,965
1,500 Added 750.0%
1,700 $36,000
Q4 2020

Jan 21, 2021

SELL
$207.01 - $276.09 $993,648 - $1.33 Million
-4,800 Reduced 96.0%
200 $2,000
Q1 2020

May 07, 2020

BUY
$199.77 - $247.81 $39,954 - $49,562
200 Added 4.17%
5,000 $11,000
Q1 2019

May 10, 2019

SELL
$163.73 - $194.7 $2.42 Million - $2.88 Million
-14,800 Reduced 75.51%
4,800 $67,000
Q4 2018

Feb 05, 2019

BUY
$151.91 - $192.21 $653,213 - $826,503
4,300 Added 28.1%
19,600 $176,000
Q3 2018

Nov 07, 2018

SELL
$167.73 - $192.74 $419,325 - $481,850
-2,500 Reduced 14.04%
15,300 $75,000
Q2 2018

Aug 10, 2018

BUY
$145.72 - $169.96 $597,452 - $696,836
4,100 Added 29.93%
17,800 $124,000
Q1 2018

May 11, 2018

SELL
$151.6 - $177.13 $5.44 Million - $6.36 Million
-35,900 Reduced 72.38%
13,700 $164,000
Q4 2017

Jan 17, 2018

SELL
$137.28 - $155.55 $4.09 Million - $4.64 Million
-29,800 Reduced 37.53%
49,600 $207,000
Q3 2017

Oct 17, 2017

BUY
$148.13 - $162.24 $11.8 Million - $12.9 Million
79,400
79,400 $212,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.